EUVIMEDEUVIMED entdecken
Crossref

L26/O-287 Human recombinant hyaluronidase increases denudation time without improving fertilization or blastocyst quality: a paired sibling-oocyte study in donor cycles

L. Morente, I. Bernal Araque, G. Tribbioli, S. Rovira, M. Antich, F. Boninu, L. Acín, F. Moffa, S. Novo

Human Reproduction · 01.07.2026 · 41 (Supplement_1)

DOI: 10.1093/humrep/deag083.285 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von L. Morente und 8 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study question What differences exist between human recombinant and bovine hyaluronidase in terms of laboratory workflow and embryological outcomes in sibling-oocyte donor cycles? Summary answer Human recombinant hyaluronidase prolonged denudation time but did not improve fertilization, usable blastocyst or high-quality blastocyst rates compared with bovine hyaluronidase. What is known already Previous studies comparing bovine and human recombinant hyaluronidase have reported similar fertilization and embryo development outcomes. However, all published work has focused solely on biological endpoints. No study has quantified denudation time, despite being a critical and time-sensitive step that may influence mechanical handling, oocyte stress, operator workload and coordination with ICSI procedures. Human recombinant hyaluronidase is biochemically more specific and batch-consistent than bovine-derived formulations, but its real-world impact on procedural efficiency remains unknown. Understanding how enzyme type affects denudation dynamics is essential for optimising laboratory workflow and protocol selection in high-volume IVF settings. Study design, size, duration Prospective sibling-oocyte study including 22 donors, resulting in 44 recipient cycles performed during 2025. Within each donor, sibling cumulus–oocyte complexes (COCs) were equally allocated to denudation with a bovine hyaluronidase preparation (Ferticult® Flushing Medium, FertiPro NV, Belgium) or human recombinant hyaluronidase (Cumulase®, CooperSurgical, USA). Denudation time was prospectively recorded at the individual COC level in a predefined subgroup of 10 donors. The study was conducted during 2025 under identical laboratory conditions. Participants/materials, setting, methods Each COC was exposed for 30 seconds to the assigned enzyme, washed, and mechanically denuded until the zona pellucida was free of cumulus cells and oocyte maturity could be assessed. Denudation time was recorded per COC and analysed only for metaphase II oocytes. All denudations were performed by the same experienced operator. Parallel ICSI cycles evaluated fertilization (2PN), post-ICSI degeneration, usable and high-quality blastocyst (≥3BB-Gardner). Paired comparisons used the Wilcoxon signed-rank test. Main results and the role of chance In the subgroup of 10 donors in whom denudation time was recorded, a total of 170 COCs yielding MII oocytes were analysed: 87 denuded with Cumulase® and 83 with bovine hyaluronidase. Cumulase® significantly increased denudation time in all donors. Mean denudation time per COC was 55.7±9.6 seconds with Cumulase® and 42.5±7.2 seconds with bovine hyaluronidase, corresponding to a mean paired difference of + 13.2 seconds (+23.7%; p < 0.05). Embryological outcomes were evaluated in all 22 donors (44 recipient cycles). Fertilization rates were comparable between enzymes (%2PN: 73.7±21.6% with Cumulase® vs 75.3±13.5% with bovine hyaluronidase; p = 0.79). Post-ICSI degeneration rates were also comparable (8.0 ± 10.8% vs 6.2 ± 9.8%; p = 0.67). Among normal fertilized oocytes, the proportion of usable blastocysts did not differ significantly (63.0±19.8% vs 54.6±22.7%, p = 0.16). Similarly, the proportion of high-quality blastocysts among usable blastocysts was comparable between groups (76.7±32.4% vs 88.9±20.1%, p = 0.22). Overall, enzyme choice significantly affected procedural efficiency, as reflected by denudation time, but did not influence fertilization or subsequent embryological competence. The paired sibling-oocyte design minimises confounding and supports the robustness of these findings. Limitations, reasons for caution Single-centre study. Denudation time was analysed in a predefined subgroup of donors. The study was not powered to detect small differences in blastocyst-related outcomes, and results may differ in laboratories applying different denudation protocols. Wider implications of the findings Under strict and standardized laboratory conditions, human recombinant hyaluronidase prolongs denudation time without clear advantages in embryological outcomes. Denudation time represents an operational parameter that should be considered when selecting and benchmarking denudation protocols. Trial registration number No

Zitieren

APA

Morente, L., Araque, I. B., Tribbioli, G., Rovira, S., Antich, M., Boninu, F., Acín, L., Moffa, F., & Novo, S. (2026). L26/O-287 Human recombinant hyaluronidase increases denudation time without improving fertilization or blastocyst quality: a paired sibling-oocyte study in donor cycles. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.285

Vancouver

Morente L, Araque IB, Tribbioli G, Rovira S, Antich M, Boninu F, et al. L26/O-287 Human recombinant hyaluronidase increases denudation time without improving fertilization or blastocyst quality: a paired sibling-oocyte study in donor cycles. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.285

BibTeX
@article{Morente2026,
  author = {Morente, L. and Araque, I. Bernal and Tribbioli, G. and Rovira, S. and Antich, M. and Boninu, F. and Acín, L. and Moffa, F. and Novo, S.},
  title = {L26/O-287 Human recombinant hyaluronidase increases denudation time without improving fertilization or blastocyst quality: a paired sibling-oocyte study in donor cycles},
  journal = {Human Reproduction},
  year = {2026},
  volume = {41},
  number = {Supplement_1},
  doi = {10.1093/humrep/deag083.285}
}
Kostenlos starten →